详细信息
半夏泻心方及配伍药组含药血清抑制人胃癌BGC-823细胞增殖的实验研究 被引量:6
Experimental study of Banxia Xiexin Prescription and druggroup in a prescription on control BGC-823 cell multiplication of human gastric cancer
文献类型:期刊文献
中文题名:半夏泻心方及配伍药组含药血清抑制人胃癌BGC-823细胞增殖的实验研究
英文题名:Experimental study of Banxia Xiexin Prescription and druggroup in a prescription on control BGC-823 cell multiplication of human gastric cancer
作者:王萍[1];李娟[1];刘喜平[1];李德兴[2];高波[2];邱桐
第一作者:王萍
机构:[1]甘肃中医学院,甘肃兰州730000;[2]甘肃省医学科学研究院,甘肃兰州730000
第一机构:甘肃中医药大学
年份:2005
卷号:22
期号:5
起止页码:14
中文期刊名:甘肃中医学院学报
外文期刊名:Journal of Gansu College of Traditional Chinese Medicine
基金:甘肃省教育厅基金资助项目(01B-32)
语种:中文
中文关键词:半夏泻心方;人胃癌BGC-823细胞;配伍;生长抑制
外文关键词:Banxia Xiexin Prescription; BGC-823 cell of human gastric cancer;compatibility of medicines ; growth inhibitory
摘要:目的:研究半夏泻心方及其配伍药组对体外人胃癌BGC 823细胞增殖的影响。方法:采用血清药理学方法和MTT法及台盼兰染色法观察半夏泻心方及其配伍药组对体外人胃癌BGC 823细胞的敏感性及生长抑制作用。结果:辛苦组对人胃癌BGC 823细胞的生长抑制作用最强,显著高于辛开组、苦降组、辛甘组、苦甘组、甘补组(P<0.05)。结论:半夏泻心方中对BGC 823细胞增殖起主要抑制作用的药组为辛开、苦降的配伍形式。辛开、苦降配伍后(辛苦)有显著的协同增效趋势,而其他配伍药群可能存在拮抗作用。提示辛开苦降法可能是中医药防治胃癌的治则治法之一。
Objective: To study the effect of Banxia Xiexin Prescription and drug-group in a prescription to BGC-823 cell multiplication of human gastric cancer out body. Methods: Observed the sensitivity and growth inhibitory effect of Banxia Xiexin Prescription and drug-group in a prescription to BGC-823 cell out body of human gastric cancer. Results: The growth inhibitory effect of Xinku group was strongest, and prominently higher than Xinkai, Kujiang, Xingan, Kugan and Ganbu group( P 〈 0.05 ). Conclusion : Xinkai and Kujiang drug-group have main inhibitory effect to BGC-823 cell multiplication. It is positive cooperative during the compatibility of Xinkai and Xinjiang . However, it is antagonistic during others compatibility. It suggested that the method of Xinkai Kujiang is importent for cure and prevent of gastric cancer.
参考文献:
正在载入数据...